Sole 1

Cover Block

PUBLIC

Name	Sole 1
Tagline	AI-powered robotic socks with synthetic muscles to restore mobility and prevent falls for people with foot drop. [James Dyson Award, 2025]
Headquarters	Cambridge, United States [LinkedIn (company post), May 2025]
Founded	2025
Stage	Pre-Seed
Business Model	Hardware + Software
Industry	Healthtech
Technology	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout [Boston University News Service, 2026]
Funding Label	Undisclosed

Links

PUBLIC

• Website: https://thesole1.com
• LinkedIn: https://www.linkedin.com/company/sole1

Executive Summary

PUBLIC

Sole 1 is a pre-seed healthtech venture developing a soft, AI-powered robotic sock to restore mobility for individuals with foot drop, a condition that merits investor attention for its combination of a large, underserved patient population and a novel technical approach to a decades-old problem. The company originated as a student project at Harvard, winning the US 2025 James Dyson Award, which provides non-dilutive validation of its core concept [James Dyson Award, 2025]. Its product, branded Sole¹, differentiates from rigid orthotics by using fabric-embedded synthetic muscles and AI-based gait tracking to both assist and rehabilitate movement, aiming for comfort and everyday wearability [James Dyson Award, 2025].

Founders Bradley Wagman and Viktor Bokisch, Harvard engineering students, have steered the project from academic concept to award-winning prototype, though their operational experience beyond this development phase is not yet publicly documented [Boston University News Service, 2026]. No formal venture funding rounds have been publicly disclosed, placing the company in a classic pre-seed, prototype-to-product transition phase with a hardware-plus-software business model typical of medical devices. The critical watchpoints over the next 12-18 months are the company's ability to secure its first institutional capital, initiate regulatory clearance processes, and move from user testing to initial commercial partnerships.

Data Accuracy: YELLOW -- Core product claims and founding story are confirmed by award and university sources; funding and team details beyond the founders are not independently corroborated.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	Hardware + Software
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Undisclosed

Company Overview

PUBLIC

Sole 1 is a medical device startup founded in 2025 by Harvard engineering students Bradley Wagman and Viktor Bokisch [Boston University News Service, 2026]. The company is based in Cambridge, Massachusetts, and emerged from a student-led project focused on developing a soft robotic solution for foot drop, a condition that impairs a person's ability to lift the front of the foot. Its primary public milestone came later that year when its product, Sole¹, was named the US 2025 James Dyson Award National Winner, a recognition that includes prize money and design validation [James Dyson Award, 2025].

The company's public narrative positions it as an academic spinout transitioning from a prototype to a commercial venture. Beyond the Dyson Award, no other formal funding rounds, regulatory clearances, or commercial deployments have been publicly disclosed. The available record shows no evidence of incorporation filings, venture capital rounds on Crunchbase, or a detailed team page beyond the founders' academic affiliations.

Data Accuracy: YELLOW -- Founders and headquarters confirmed by a university news service; founding year and award status confirmed by primary award source. No independent corporate record or state filing verification.

Product and Technology

MIXED Sole 1's core proposition is a hardware and software system designed to address a specific, high-impact mobility impairment. The product, branded Sole¹, is described as an AI-powered robotic sock intended to restore mobility for individuals with foot drop, a condition often resulting from stroke, multiple sclerosis, or other neurological injuries [James Dyson Award, 2025]. The device aims to track, train, and physically assist walking to prevent falls and support nerve recovery, positioning itself as both an assistive and rehabilitative tool [Perplexity Sonar Pro Brief, retrieved 2024].

The technical differentiation hinges on its material and control system. Unlike traditional rigid ankle-foot orthoses (AFOs) or bulkier exoskeletons, Sole¹ uses fabric-embedded synthetic muscles to provide dynamic physical assistance, a choice aimed at improving comfort and everyday wearability [Perplexity Sonar Pro Brief, retrieved 2024]. An integrated AI system is tasked with orchestrating the wearer's gait in real-time, analyzing movement to ensure what the company calls natural and secure motion [James Dyson Award / YouTube, 2025]. This combination of soft robotics and adaptive control software is the central technological bet.

Public details on the technology stack, sensor specifications, battery life, or regulatory status are not disclosed. The available materials, including the award submission and a promotional video, focus on the functional outcome and user benefit rather than engineering specifics. The system appears to be in a prototype stage, with no public information on manufacturing partners, software development kits, or integration capabilities.

Data Accuracy: YELLOW -- Product claims are consistent across the James Dyson Award materials and company social media, but technical specifications and development status are not independently verified.

Market Research

MIXED The market for foot drop treatment devices is defined by a persistent, unmet clinical need for comfortable, active rehabilitation tools, a gap that new technologies like Sole 1's are attempting to fill. The condition, which impairs the ability to lift the front of the foot, affects an estimated 1 in 5 stroke survivors and is a common complication of multiple sclerosis, spinal cord injury, and other neurological disorders [GII Research, 2026]. The primary driver for any new entrant is the documented dissatisfaction with existing solutions, which are often cited by patients as bulky, uncomfortable, or purely passive, leading to poor compliance and continued fall risk.

Third-party market sizing for the specific category of foot drop treatment devices provides a baseline for the commercial opportunity. According to a 2026 market forecast report, the global market for these devices was projected to reach approximately $1.2 billion by 2030, growing at a compound annual rate of 7.8% from a 2024 base [GII Research, 2026]. This growth is attributed to an aging global population, rising prevalence of neurological conditions, and increasing patient demand for advanced, non-invasive mobility aids. The report segments the market by product type, with functional electrical stimulation (FES) devices and ankle-foot orthoses (AFOs) representing the dominant categories.

Metric	Value
Global Market 2024	0.9 $B
Global Market 2030 (projected)	1.2 $B
CAGR 2024-2030	7.8 %

This chart illustrates a steady, single-digit growth trajectory for the established device market, a figure that likely understates the potential disruption from novel, AI-integrated products that could expand the addressable market by improving user adherence and clinical outcomes. The adjacent and substitute markets are significant, including the broader physical therapy and rehabilitation equipment sector, valued in the tens of billions, and the consumer wellness wearables market. Sole 1's positioning at the intersection of medical device and consumer wearable suggests an ambition to capture value from both regulated healthcare reimbursement and direct-to-consumer channels, though the latter is far more challenging for a Class II medical device.

Key regulatory and macro forces will heavily influence market entry. In the United States, the path to commercialization requires FDA clearance, most likely under the 510(k) pathway by demonstrating substantial equivalence to a predicate device, such as an existing FES system or orthosis. This process imposes significant time and capital costs. Furthermore, reimbursement from Medicare and private insurers is not guaranteed for a new device category and would require clinical outcome studies to prove superior efficacy or cost-effectiveness over standard care. Macro tailwinds, however, are favorable, including increased venture investment in digital health and rehabilitation tech, as well as a broader societal focus on aging in place and technologies that support independent living.

Data Accuracy: YELLOW -- Market sizing from a single third-party report; clinical prevalence and growth drivers are consistent with broader industry analysis.

Competitive Landscape

MIXED Sole 1 enters a rehabilitation hardware market defined by established medical devices and a newer wave of tech-forward challengers, with its primary claim resting on a novel form factor and active AI assistance.

No named competitors were identified in the company's public materials or captured sources, precluding a direct comparison table. The analysis below is based on a review of the broader market category.

Competition for Sole 1's robotic sock can be mapped across three distinct segments. First, the incumbent category consists of traditional, passive ankle-foot orthoses (AFOs), which are rigid braces prescribed by clinicians to stabilize the foot. These devices, from companies like Ottobock and Fillauer, dominate the current standard of care due to insurance reimbursement pathways and clinical familiarity, but they offer no active assistance or rehabilitation feedback [GII Research, 2026]. The second segment includes functional electrical stimulation (FES) devices, such as the Bioness L300 or the Cionic Neural Sleeve, which use electrodes to stimulate nerves and cause muscles to contract. These represent a more direct technological challenger to Sole 1, as they are active, wearable systems aimed at restoring movement, though they rely on a different underlying mechanism (electrical stimulation vs. synthetic muscles) [Reddit, 2026]. The third, adjacent segment comprises robotic exoskeletons for the lower limb, which are typically bulkier, higher-power systems used in clinical settings for gait training; these are not substitutes for daily wear but compete for rehabilitation budgets and mindshare.

Sole 1's current edge is almost entirely conceptual, anchored in its unique integration of fabric-embedded synthetic muscles and AI-driven gait orchestration. The James Dyson Award recognition provides a durable signal of technical innovation and design thinking that may aid in securing early research grants and attracting engineering talent [James Dyson Award, 2025]. The proposed form factor,a sock,is a clear point of differentiation aimed at comfort and discretion, addressing a common complaint about the bulk and discomfort of traditional AFOs and FES units. This edge is perishable, however, as it is currently protected only by the novelty of the prototype, not by demonstrated intellectual property, manufacturing scale, or clinical validation.

The company's most significant exposure lies in the commercial and regulatory moats built by incumbents. Firms like Ottobock have decades of experience navigating the FDA's 510(k) clearance process for Class II medical devices and have established distribution networks through orthotic and prosthetic clinics. Furthermore, the reimbursement landscape for durable medical equipment is complex and favors established billing codes for existing device categories. Sole 1 also faces potential competition from the FES segment, where companies like Cionic are advancing their own AI-powered, soft wearable systems and may be quicker to market with a regulatory-cleared product [Reddit, 2026]. Sole 1 does not yet own any channel to patients or clinicians.

The most plausible 18-month scenario sees the competitive field clarifying around which novel technology can first secure regulatory clearance and a pilot deployment with a paying healthcare institution. In this scenario, the "winner" would be whichever company,be it Sole 1 or a FES challenger,first publishes positive user study data in a peer-reviewed journal, translating design awards into clinical credibility. The "loser" would be any player that remains in the prototype and award cycle without progressing to a pivotal regulatory study, finding itself outpaced in the race for early adopters and partnership capital.

Data Accuracy: YELLOW -- Competitive mapping is inferred from general market reports and user discussions; no direct competitor citations from the company are available.

Opportunity

PUBLIC If Sole 1 can translate its award-winning prototype into a cleared medical device, it targets a multi-billion dollar market for a condition with chronic, underserved demand.

The headline opportunity is to become the first widely adopted, soft-robotic alternative to traditional ankle-foot orthoses (AFOs) for foot drop, a condition affecting millions globally. The cited evidence points to a product designed for everyday wearability and active rehabilitation, not just passive support, which addresses a core complaint about existing bulky braces [James Dyson Award, 2025]. The James Dyson Award recognition validates the innovation's design and potential impact, providing a non-dilutive platform that could accelerate initial clinical and commercial interest. The outcome is reachable because the problem is well-defined, the solution is a direct response to patient-reported discomfort, and the regulatory pathway for Class II medical devices, while rigorous, is established.

Growth would likely follow one of several concrete paths, each with a distinct catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Direct-to-Consumer Rehab	Sole¹ is prescribed by neurologists and physiatrists as a premium, patient-owned rehabilitation device, capturing high-margin sales.	Securing FDA 510(k) clearance as a powered orthosis, enabling direct marketing to clinicians and patients.	The device is framed as a mobility and recovery aid, fitting a growing trend of patient-centric, at-home medical tech [Boston Globe, September 2025].
Institutional Land-and-Expand	Sole 1 first sells into top-tier rehabilitation hospitals and MS treatment centers, then expands to skilled nursing facilities and VA networks.	A pivotal clinical study partnership with a major academic medical center demonstrating reduced fall risk and improved gait metrics.	Early materials emphasize clinical testing and rehabilitation, aligning with institutional procurement cycles for therapeutic equipment [James Dyson Award, 2025].
Platform Expansion	The core synthetic muscle and AI gait engine is licensed or adapted for adjacent mobility impairments beyond foot drop, such as post-stroke gait or cerebral palsy.	Successful user data from the initial foot drop cohort demonstrates the AI's ability to safely adapt to varied, unpredictable gait patterns.	The technology's premise is dynamic, AI-driven assistance for natural movement, a platform capability hinted at in its description [Perplexity Sonar Pro Brief].

Compounding for Sole 1 would manifest as a data-driven clinical moat. Each device in use would generate proprietary gait data, continuously refining the AI's assistance algorithms. Superior outcomes data, derived from this closed-loop system, would strengthen clinical validation, drive further physician prescriptions, and create a barrier for competitors relying on static, pre-programmed devices. The flywheel starts with the first cohort of users providing the real-world movement data necessary to train a more responsive and personalized system, a feedback loop explicitly mentioned in the product's description of tracking and training [James Dyson Award, 2025].

The size of the win can be framed by looking at the established market it seeks to disrupt. The global foot drop treatment devices market was projected to reach several billion dollars by the end of the decade [GII Research, 2026]. A credible comparable is the valuation of public orthotics and prosthetics (O&P) companies, or the acquisition multiples for innovative neurostimulation devices like those from Bioness. If the "Direct-to-Consumer Rehab" scenario plays out and Sole 1 captures a single-digit percentage of the high-end AFO and functional electrical stimulation (FES) segment, the company could support a valuation in the high hundreds of millions of dollars (scenario, not a forecast). This outcome hinges on achieving regulatory clearance and demonstrating superior patient compliance and outcomes versus existing alternatives.

Data Accuracy: YELLOW -- The market size and competitive context are cited from industry reports. The company's specific path to scale and compounding effects are inferred from its public product claims and award materials.

Sources

PUBLIC

1. [James Dyson Award, 2025] Sole¹ | James Dyson Award , https://www.jamesdysonaward.org/en-US/2025/project/sole

2. [James Dyson Award / YouTube, 2025] Sole¹ | US 2025 James Dyson Award National Winner , https://www.youtube.com/watch?v=MyjJWaiLLoY

3. [LinkedIn (company post), May 2025] Sole 1 James Dyson Award announcement , https://www.linkedin.com/posts/sole1_sole1-jamesdysonaward-footdrop-activity-7374119303853387776-_Vfz

4. [Boston Globe, September 2025] Harvard engineering students create robotic sock for disabled people , https://www.bostonglobe.com/2025/09/15/business/harvard-robotic-sock-ai/

5. [Boston University News Service, 2026] From robotics class to start-ups: Meet the engineering students who are modernizing mobility devices , https://bunewsservice.com/from-robotics-class-to-start-ups-meet-the-engineering-students-who-are-modernizing-mobility-devices/

6. [Facebook (Harvard GSD), 2026] Sole 1, developed by Bradley Scott Wagman (MDE '26) ... , https://www.facebook.com/HarvardGSD/posts/sole-1-developed-by-bradley-scott-wagman-mde-26-ceo-and-co-founder-alongside-vik/1439003011594925/

7. [Reddit, 2026] r/MultipleSclerosis on Reddit: Bioness vs. Cionic opinions and experiences with foot drop and unstable gait? , https://www.reddit.com/r/MultipleSclerosis/comments/1cuk26s/bioness_vs_cionic_opinions_and_experiences_with/

8. [GII Research, 2026] Foot Drop Treatment Devices Global Market Report 2026 , https://www.giiresearch.com/report/tbrc1945216-foot-drop-treatment-devices-global-market-report.html

9. [Perplexity Sonar Pro Brief] Sole 1 product claims , retrieved 2024